Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement with Monte RosaMonte
Novartis is testing a new drug for a joint disease called psoriatic arthritis. This means Monte Rosa's medicine is moving forward, which shows promise for the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.